Inoviq Ltd
Research Inoviq Ltd (IIQ) on Bullrun: market cap AUD 26.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIIQ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyAUD
- Market capAUD 26.04M
- Financial periodFY2025
Valuation Snapshot
latest market cap is AUD 26.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.06 | n/a | n/a | n/a |
| FY2024 | AUD 535.12K | -AUD 6.55M | -AUD 4.50M | 84.9% | -0.07 | AUD 9.23M | AUD 403.74K | AUD 19.99M |
| FY2023 | AUD 398.19K | -AUD 8.97M | -AUD 7.32M | 88.8% | -0.1 | AUD 7.81M | AUD 730.71K | AUD 19.62M |
| FY2022 | AUD 276.75K | -AUD 18.20M | -AUD 6.47M | 79.6% | -0.07 | AUD 15.39M | AUD 998.69K | AUD 28.29M |
| FY2021 | AUD 468.10K | -AUD 12.37M | -AUD 6.05M | 86.3% | n/a | AUD 9.02M | AUD 1.26M | AUD 27.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | AUD 26.04M | n/a | n/a | n/a |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Inoviq Ltd's market cap?
Inoviq Ltd's market capitalization is AUD 26.04M.
What does Inoviq Ltd do?
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.